In a recent public advisory, the National Agency for Food and Drug Administration and Control (NAFDAC) has raised concerns about the performance of Abbott’s m-PIMA HIV-1/2 VL test kits. These kits, designed for HIV detection, have reportedly failed to meet performance claims for specific HIV-1 groups, posing potential risks to patient health.
The revelation came to light through Abbott’s internal stability monitoring programme, prompting NAFDAC to issue a cautionary statement to healthcare providers. According to NAFDAC, the affected test kits failed to meet performance standards for HIV-1 groups O and HIV-1 group M and N throughout their claimed shelf life. It’s worth noting that the performance for HIV-2 remains unaffected.
Abbott has initiated an investigation to identify the root cause of this issue and will implement corrective actions to prevent similar incidents in the future. Rigorous statistical analysis was employed to pinpoint the impacted lots, ensuring a targeted response.
The m-PIMA HIV-1/2 VL cartridge, categorized as a point-of-care nucleic acid test (NAT), utilizes Polymerase Chain Reaction (PCR) technology to directly quantify HIV type 1 groups M/N and O, along with HIV type 2 RNA in human plasma samples. NAFDAC has underscored the potential consequences of inaccurate results for patients belonging to the affected HIV-1 groups, including delayed follow-up, improper treatment adjustments, progression of infection, and deterioration of patient health.
NAFDAC has called upon healthcare professionals and consumers to remain vigilant, urging them to report any suspicions of adverse reactions, substandard or falsified medicines, diagnostic devices, and other regulated products to the nearest NAFDAC office. The agency’s proactive stance aims to ensure public safety and prompt intervention in the face of potential health risks associated with faulty medical products.
Please follow and like us:
Post Views:159
Related Posts:
NAFDAC Issues Public Alert Regarding Circulation of… The National Agency for Food and Drugs Administration and Control (NAFDAC) has raised a red flag concerning the presence of counterfeit Meronem 1g Injection in circulation in Nigeria. This alert, detailed in a public notice…
Nigerian firm to produce HIV/malaria test kits. Abuja, Nigeria – In a groundbreaking development for Nigeria’s healthcare sector, a local biotechnology firm has announced plans to commence the production of HIV and malaria test kits. This initiative is expected to strengthen Nigeria’s…
NAFDAC Issues Warning: Avoid Recalled High-Caffeine… The National Agency for Food and Drugs Administration and Control (NAFDAC) has issued a public warning, urging consumers to steer clear of G Fuel brand Energy Drinks due to their significantly high caffeine content. This…
NAFDAC's Plan to Review Sanctions on Exporters of… The National Agency for Food and Drug Administration and Control (NAFDAC) has announced its intention to review the sanctions imposed on exporters of substandard products [1]. This decision comes in response to the increasing rejection of…
